VINCRISTINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C46H56N4O10
Molecular Weight	824.9594
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@@]1(C[C@@]2([H])C[C@](c3cc4c(cc3OC)N(C=O)[C@]5([H])[C@@]64CCN7CC=C[C@](CC)([C@@]67[H])[C@]([H])([C@@]5(C(=O)OC)O)OC(=O)C)(c8c(CCN(C2)C1)c9ccccc9[nH]8)C(=O)OC)O

InChI

InChIKey=OGWKCGZFUXNPDA-CFWMRBGOSA-N

InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00541
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/vincristine.html

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.Vincristine was marketed under the brand name Oncovin, but was discontinued. In 2012 the FDA approved a Liposomal formulation of Vincristine, named MARQIBO KIT.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
transformed cell apoptotic process 104 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19137911	Activator 1343
Tubulin beta chain 8 Target ID: P07437 Gene ID: 203068.0 Gene Symbol: TUBB Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00541	Inhibitor 7728
microtubule polymerization 18 Target ID: GO:0046785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10920282	Inhibitor 7728	1.6 µM [IC50]
CCRF-CEM 4 Target ID: CHEMBL382 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22582991	Inhibitor 7728	0.17 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202497s000lbl.pdf	Primary		Approved 8043	Marqibo Approved Use Marqibo® is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Launch Date 1.34438401E12

C_max

Value	Dose	Co-administered	Analyte	Population
1220 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000PharmR.pdf	2.25 mg/m² steady-state, intravenous dose: 2.25 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:		VINCRISTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
14566 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000PharmR.pdf	2.25 mg/m² steady-state, intravenous dose: 2.25 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:		VINCRISTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
25% OTHER GOV https://www.medsafe.govt.nz/profs/Datasheet/v/Vincristinesulfatempinj.pdf			VINCRISTINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2.25 mg/m2 1 times / week multiple, intravenous MTD Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 18 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	DLT: Motor polyneuropathy, Seizure... Dose limiting toxicities: Motor polyneuropathy (grade 3, 14.3%) Seizure (grade 4, 14.3%) Hepatotoxicity (grade 4, 14.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	DLT: Neutropenia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 33.3%) Thrombocytopenia (grade 4, 33.3%) Obstipation Myalgia (grade 3, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
2.4 mg/m2 3 times / week multiple, intravenous MTD Dose: 2.4 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704	unhealthy, 32-83 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704	Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704
2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	Disc. AE: Peripheral neuropathy, Tumor lysis syndrome... AEs leading to discontinuation/dose reduction: Peripheral neuropathy (10%) Tumor lysis syndrome (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8

AEs

AE	Significance	Dose	Population
Motor polyneuropathy	grade 3, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Hepatotoxicity	grade 4, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Seizure	grade 4, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Obstipation	DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Myalgia	grade 3, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Neutropenia	grade 4, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Thrombocytopenia	grade 4, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Peripheral neuropathy	10% Disc. AE	2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8
Tumor lysis syndrome	2% Disc. AE	2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601		substrate 1118	inhibitor 1475

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C19 910 P-gp 1400

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C19 910	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31 Page: 31.0	likely
CYP2D6 1118	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31 Page: 31.0	likely
P-gp 1400	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/17029589/	yes
CYP3A4 1601	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31; https://pubmed.ncbi.nlm.nih.gov/10613614/ Page: 31.0	yes	yes (co-administration study) Comment: the total area under the plasma concentration-time curve was 43% smaller in patients who were receiving carbamazepine or phenytoin than in the control group; the concomitant use of strong CYP3A inhibitors should be avoided (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin). Similarly, the concomitant use of strong CYP3A inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John’s Wort) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31; https://pubmed.ncbi.nlm.nih.gov/10613614/ Page: 31.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1507	inhibitor 1489 Sources: https://pubmed.ncbi.nlm.nih.gov/15812674/ Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	E375
AbovChem LLC	HY-N0488
BOC Sciences	2068-78-2
BioSynth	Q-201925
Biopurify Phytochemicals	BP1439
Biopurify Phytochemicals	BP1440
Bosche Scientific	V1207
Cayman Chemical	11764
Chem Scene	CS-1778
Hangzhou APIChem Technology	AC-22619
Hangzhou Yuhao Chemical Technology	RT14234
IBScreen	STOCK1N-40733
KeyOrganics	AS-12168
MedChem Express	HY-N0488
MolPort	MolPort-002-519-272
MolPort	MolPort-003-939-860
MolPort	MolPort-035-789-673
Sigma Aldrich	1714007
Sigma Aldrich	V0400000
Sigma Aldrich	V0400000\|SIAL
Sigma Aldrich	V8388\|SIAL
Sigma Aldrich	V8879\|SIGMA
ZINC	ZINC000085537024	http://zinc15.docking.org/substances/ZINC000085537024
eMolecules	32176538
eMolecules	50241482
eMolecules	95704370
mcule	MCULE-1562099693
mcule	MCULE-3827132352

PubMed

Title	Date	PubMed
Vincristine-induced myocardial infarction.	1975 Dec	1243105
Vincristine-induced autonomic neuropathy.	1975 Jul 26	1148735
[Superiority of intrafascicular neurography over conventional nerve conduction studies in evaluating axonal degeneration].	1999 Apr	10363265
Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.	1999 Apr 29	10348353
Pain related behaviour during vincristine-induced neuropathy in rats.	1999 Apr 6	10321468
Vincristine revisited.	1999 Feb	10226730
Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma.	1999 Jul	10457124
Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis.	1999 Mar	10217912
[Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease].	1999 May	10390891
Low-dose vincristine-associated bilateral vocal cord paralysis.	1999 Oct	10578547
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.	1999 Oct	10515904
Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol--in vitro explant study.	1999 Oct 22	10553948
Clinical and electrophysiological studies in vincristine induced neuropathy.	1999 Sep	10499201
Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells.	1999 Sep	10454517
Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.	2000	11030069
The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.	2000 Aug	10900222
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.	2000 Mar	10741703
[Severe hemolysis and SIADH-like symptoms induced by vincristine in an ALL patient with liver cirrhosis].	2000 Nov	11193445
Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients.	2000 Oct	11194540
Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat.	2000 Sep 4	10931481
Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.	2001	11458812
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.	2001 Apr	11328296
Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death.	2001 Aug 3	11478917
Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100.	2001 Feb 16	11178967
Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.	2001 Jul	11438417
Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.	2001 Mar	11255732
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.	2001 Mar	11241435
Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport.	2001 May 11	11278867
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.	2001 May 18	11355937
Delayed functional recovery by vincristine after sciatic nerve crush injury: a mouse model of vincristine neurotoxicity.	2001 May 18	11335041
Ischemic heart disease associated with vincristine and doxorubicin chemotherapy.	2001 Nov	11724093
Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.	2001 Oct 15	11587867
Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL.	2001 Sep	11716366
Massive cell death of cerebellar granule neurons accompanied with caspase-3-like protease activation and subsequent motor discoordination after intracerebroventricular injection of vincristine in mice.	2002	12401321
Effect of thiopental, propofol, and etomidate on vincristine toxicity in PC12 cells.	2002	11991087
Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins.	2002 Apr	11934808
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.	2002 Apr 15	11956280
Identification and characterization of the canine multidrug resistance-associated protein.	2002 Dec	12516967
Treatment results of aggressive B non-Hodgkin's lymphoma in advanced age considering comorbidity.	2002 Dec	12437637
Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation.	2002 Dec 15	12490805
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.	2002 May 1	12015757
Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.	2002 Nov-Dec	12465768
Vincristine-itraconazole interaction: cause for increasing concern.	2002 Oct	12368705
Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat.	2003 Aug 1	12865165
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.	2003 Jul 15	12874004
Bilateral hearing loss during vincristine therapy: a case report.	2003 Jun	12868558
The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells.	2003 May 16	12706485
Functional expression of the multidrug resistance protein 1 in microglia.	2003 Oct	12893836

Patents

Sample Use Guides

In Vivo Use Guide

Marqibo is liposome-encapsulated vincristine. 2.25 mg/m2 intravenously over 1 hour once every 7 days.

Route of Administration: Intravenous

In Vitro Use Guide

Treatment of macrophage monolayers for 24 h with vincristine (10(-5)-10(-7) M) inhibited the antibody dependent cellular cytotoxicity (ADCC) by PMA stimulated rat macrophages.

Name

Type

Language

VINCRISTINE

Official Name

English

(+)-VINCRISTINE

Common Name

English

22-OXOVINCALEUKOBLASTINE

Common Name

English

VINCALEUKOBLASTINE, 22-OXO-

Common Name

English

ONCOTCS

Brand Name

English

VINCRISTINE [WHO-DD]

Common Name

English

VINCRISTINE [VANDF]

Common Name

English

TECNOCRIS

Brand Name

English

VINCRISTINE [MI]

Common Name

English

VINCRISTINE [HSDB]

Common Name

English

VINKRISTIN

Common Name

English

VCR

Common Name

English

LEUROCRISTINE

Common Name

English

LEUCRISTINE

Common Name

English

VINCRISTINE [INN]

Common Name

English

VINCRISTIN

Common Name

English

Classification Tree Code System Code

WHO-VATC

QL01CA02